Esketamine Clinical Trial
Official title:
Median Effective Dose of Esketamine Pretreatment to Prevent Sufentanil-induced Cough
Sufentanil has the advantages of fast onset time, strong analgesic function and cardiovascular stability, and is widely used during general anesthesia induction. However, sufentanil can cause cough during induction of general anesthesia. Different studies have reported that the incidence of sufentanil-induced cough ( SIC ) during anesthesia is 16-42 %. This pathological condition may lead to damage to the central nervous system, increase the risk of reflux and aspiration, increase intracranial pressure and intraocular pressure, and endanger patients with cerebral aneurysms and ocular trauma. Therefore, at the moment of advocating comfortable anesthesia medical services, sufentanil-induced cough response is a problem that clinical anesthesiologists need to focus on and urgently solve. It has been reported that ketamine can reduce the incidence of cough caused by opioids. Esketamine is a pure dextro-enantiomer of ketamine and an NMDA antagonist with potent analgesic and bronchodilator effects. In this study, Dixon sequential method was used to study the median effective dose ( ED50 ) of intravenous esketamine pretreatment to prevent sufentanil-induced cough, and to explore the effect of age on ED50. To provide reference for clinical rational selection of esketamine dose.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05506787 -
The Effects of Intraoperative Esketamine on Postoperative Pain and Mood in Patients With Inflammatory Bowel Disease
|
Phase 4 | |
| Not yet recruiting |
NCT06062550 -
Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery
|
Phase 4 | |
| Recruiting |
NCT06003218 -
Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation
|
N/A | |
| Recruiting |
NCT04664530 -
The Study on the Esketamine in the Treatment of Postherpetic Neuralgia
|
Phase 4 | |
| Not yet recruiting |
NCT06117917 -
Esketamine Combined With Pregabalin on CPSP in Spinal Patients.
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05950646 -
Mini-dose Dexmedetomidine-Esketamine Infusion and Perioperative Sleep Quality
|
Phase 4 | |
| Recruiting |
NCT05718024 -
Night-time Dexmedetomidine-esketamine Infusion and Sleep Quality With Mechanical Ventilation
|
Phase 4 | |
| Recruiting |
NCT05732064 -
Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality
|
Phase 4 | |
| Not yet recruiting |
NCT06389344 -
Effect of Esketamine on Conscious State in Patients With pDoC
|
N/A | |
| Recruiting |
NCT04860661 -
Esketamine on Postpartum Depression in Cesarean Section Women
|
N/A | |
| Completed |
NCT06398834 -
Esketamine and Butorphanol for Post-Lobectomy Pain
|
Phase 4 | |
| Recruiting |
NCT06399185 -
Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort
|
Phase 4 | |
| Recruiting |
NCT06451627 -
Esketamine on Postoperative Sleep Disturbance of Patients Undergoing Spinal Surgery
|
N/A | |
| Completed |
NCT05458453 -
An Exploratory Study of Esketamine in Patients After Thoracoscopic Surgery
|
Phase 4 | |
| Recruiting |
NCT04843982 -
Immunoinflammatory Regulation of Esketamine in Septic Patients
|
Phase 4 | |
| Not yet recruiting |
NCT06468436 -
Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients
|
N/A | |
| Not yet recruiting |
NCT05943028 -
Effect of Subanesthetic Dose Esketamine on Propofol-refentanil Closed-loop Targeted Controlled Infusion
|
Early Phase 1 | |
| Active, not recruiting |
NCT05718544 -
Mini-dose Esketamine-dexmedetomidine Supplemented Analgesia and Long-term Outcomes
|
Phase 4 | |
| Not yet recruiting |
NCT06087510 -
Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes
|
Phase 4 | |
| Recruiting |
NCT06051227 -
Fentanyl OR Esketamine for Traumatic PAIN (FORE-PAIN) Trial
|
Phase 3 |